Literature DB >> 16714124

HIV-1 protein gp120 rapidly impairs memory in chicks by interrupting the glutamate-glutamine cycle.

S P Fernandes1, T M Edwards, K T Ng, S R Robinson.   

Abstract

Learning and memory impairments are frequently observed in patients suffering from AIDS Dementia Complex (ADC). These effects have been linked to the presence of gp120, an HIV viral coat glycoprotein. The present study investigated the possibility that gp120 prevents the uptake of extracellular glutamate by astrocytes, leading to an interruption of the glutamate-glutamine cycle and a subsequent impairment of memory. Ten microliters of 10nM gp120 was bilaterally injected into the region of the intermediate medial mesopallium of day-old chicks at various times before, or after, training using a single-trial passive avoidance task. Gp120 was found to significantly impair memory retention when injected 10-40 min after training. Memory impairments were evident within 5 min of gp120 administration and remained evident 24h later. Further, the amnestic effect of gp120 could be overcome with glutamine or with precursors of glutamate synthesis, but only weakly by glutamate. These results support the conclusion that the amnestic effect of gp120 is due to an impaired uptake of glutamate by astrocytes and a subsequent interruption of glutamine supply to neurones. The data indicate that the glutamate-glutamine cycle may be a useful therapeutic target in the treatment of ADC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714124     DOI: 10.1016/j.nlm.2006.03.006

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  8 in total

1.  Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice.

Authors:  James P Kesby; Robert K Heaton; Jared W Young; Anya Umlauf; Steven P Woods; Scott L Letendre; Athina Markou; Igor Grant; Svetlana Semenova
Journal:  Neuropsychopharmacology       Date:  2015-02-05       Impact factor: 7.853

2.  Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients.

Authors:  Alex M Dickens; Daniel C Anthony; Reena Deutsch; Michelle M Mielke; Timothy D W Claridge; Igor Grant; Donald Franklin; Debra Rosario; Thomas Marcotte; Scott Letendre; Justin C McArthur; Norman J Haughey
Journal:  AIDS       Date:  2015-03-13       Impact factor: 4.177

Review 3.  Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.

Authors:  Neha Vartak-Sharma; Shruthi Nooka; Anuja Ghorpade
Journal:  Prog Neurobiol       Date:  2016-04-14       Impact factor: 11.685

4.  Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV.

Authors:  Dima A Hammoud; Christopher J Endres; Edward Hammond; Ovsev Uzuner; Amanda Brown; Avindra Nath; Adam I Kaplin; Martin G Pomper
Journal:  Neuroimage       Date:  2009-10-21       Impact factor: 6.556

5.  Cellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegeneration.

Authors:  Alison J B Markowitz; Michael G White; Dennis L Kolson; Kelly L Jordan-Sciutto
Journal:  Cellscience       Date:  2007-07-27

Review 6.  Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders.

Authors:  Michelle C Potter; Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-04       Impact factor: 4.147

Review 7.  Emerging Role of Nef in the Development of HIV Associated Neurological Disorders.

Authors:  Shadan S Yarandi; Michael R Duggan; Ilker K Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2020-10-29       Impact factor: 7.285

Review 8.  Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND).

Authors:  Vasudev R Rao; Arthur P Ruiz; Vinayaka R Prasad
Journal:  AIDS Res Ther       Date:  2014-05-19       Impact factor: 2.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.